Mechanism for treating muscle degeneration discovered
On Feb. 12, 2025, researchers at the Max Planck Institute released a study that could pave the way…
-
-
Oldest human DNA revealed family network that spanned Europe
On Dec. 12, 2024, a study led by scientists from the Max Planck Institute for Evolutionary Anthropology in…
-
Proteins that regulate animal stem cells are much older than animals themselves
On Nov. 15, 2024, an international research team including scientists from the Max Planck Institute reported that critical…
-
World-first cure for lethal skin disease achieved in landmark study
On Nov. 11, 2024, an international team of researchers has for the first time cured patients with Toxic…
-
Vaccine doses allocated to African countries hardest hit by mpox surge
On Nov. 6, 2024, the World Health Organization announced that the Access and Allocation Mechanism (AAM) for mpox…
-
National Academies reported COVID-19 vaccines don’t cause many potential harms
On Apr. 16, 2024, the National Academies of Sciences, Engineering, and Medicine reported that the COVID-19 vaccines made…
-
BioNTech aimed to start mRNA vaccine output in Rwanda in 2025
On Dec. 18, 2023, COVID-19 vaccine maker BioNTech (22UAy.DE) announced that it aims to start production at its…
-
BioNTech and Australiaﾒs State of Victoria signed agreement on strategic partnership to strengthen mRNA rcosystem
On Dec. 7, 2023, BioNTech announced that it had signed a multi-year strategic partnership with the State of…
-
Researchers document third known case of HIV remission involving stem cell transplant
On Feb. 15, 2023, it was reported that a 53-year-old man in Germany had become at least the…
-
BioNTech announced strategic partnership with UK Government to provide up to 10,000 patients with personalized mRNA cancer immunotherapies
On Jan. 5, 2023, BioNTech announced that the Company had signed a Memorandum of Understanding with the Government…
-
BioNTech and Fosun Pharma announced regulatory approval of mono- and bivalent COVID-19 vaccine COMIRNATYﾮ in individuals 12 years and older in Hong Kong
On Dec. 23, 2022, BioNTech and Fosun Pharmaceutical announced that they had received the certificates of registration as…
-
German Health Authority expanded recommendation for use of Novavax COVID-19 vaccine as a booster
On Dec. 16, 2022, Novavax announced that the Standing Committee on Vaccination (STIKO) in Germany had expanded its…
-
Biotechnology | COVID-19 | FDA | Influenza | Vaccine
Pfizer and BioNTech received U.S. FDA Fast Track Designation for single-dose mRNA-based vaccine candidate against COVID-19 and influenza
On Dec. 9, 2022, Pfizer and BioNTech announced the companies had received Fast Track Designation from the U.S….
-
Biotechnology | COVID-19 | FDA | Vaccine
Pfizer and BioNTech received U.S. FDA EUA for Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in children
On Dec. 8, 2022, Pfizer and BioNTech announced the U.S. Food and Drug Administration had granted Emergency Use…
-
Pfizer and BioNTech advancd next-generation COVID-19 vaccine
On Nov. 16, 2022, Pfizer and BioNTech announced that the companies had initiated a Phase 1 study to…
-
Pfizer and BioNTech announced updated data for Omicron BA.4/BA.5-adapted bivalent booster
On Nov. 4, 2022, Pfizer and BioNTech announced updated data from a Phase 2/3 clinical trial demonstrating a…
-
U.S. FDA recommended Novavax COVID-19 vaccine, adjuvanted as a booster in adults
On Oct. 19, 2022, the U.S. Food and Drug Administration (FDA) recommended the use of the Novavax COVID-19…
-
Biotechnology | Diagnostics | Infectious Disease | Polio | Vaccine | WHO
Global leaders committed US$ 2.6 billion at World Health Summit to end polio
On Oct. 18, 2022, global leaders confirmed US$ 2.6 billion in funding toward the Global Polio Eradication Initiative’s…
-
Pfizer and BioNTech announced positive early data from clinical trial of Omicron BA.4/BA.5-adapted bivalent booster
On Oct. 13, 2022, Pfizer and BioNTech announced early data from a Phase 2/3 clinical trial (NCT05472038) evaluating…
-
Biotechnology | CDC | COVID-19 | FDA
Pfizer and BioNTech received U.S. FDA EUA for Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine booster in children
On Oct. 12, 2022, Pfizer and BioNTech announced that the U.S. Food and Drug Administration granted Emergency Use…
-
Pfizer and BioNTech completed submission to EMA for Omicron BA.4/BA.5-adapted bivalent vaccinebBooster in children 5 through 11 years of age
On Sept. 28, 2022, Pfizer and BioNTech announced they had completed a submission to the European Medicines Agency…
-
Biotechnology | COVID-19 | FDA
Pfizer and BioNTech submitted application to U.S. FDA for EUA of Omicron BA.4/BA.5-adapted bivalent vaccine booster in children 5 through 11 years of age
On Sept. 28, 2022, Pfizer and BioNTech announced they have completed a submission to the U.S. Food and…
-
Pfizer and BioNTech completed submission to EMA for Omicron BA.4/BA.5 adapted bivalent vaccine
On Aug. 26, 2022, Pfizer and BioNTech announced they had completed a submission to the European Medicines Agency…
-
Pfizer and BioNTech announced Omicron-adapted COVID-19 vaccine candidates demonstrated high immune response
On Jun. 24 2022, Pfizer and BioNTech announced positive data evaluating the safety, tolerability, and immunogenicity of two…
-
Pfizer and BioNTech received positive CHMP Opinion for COVID-19 vaccine booster in adolescents 12 through 17 years of age in EU
On Feb. 24, 2022, BioNTech announced that the Committee for Medicinal Products for Human Use of the European…
-
BioNTech introduced first modular mRNA manufacturing facility to promote scalable vaccine production in Africa
On Feb. 16, 2022, BioNTech announced it had introduced its approach to establishing scalable vaccine production by developing…
-
Pfizer and BioNTech updated rolling submission for EUA of COVID-19 caccine in children 6 months through 4 years of Age
On Feb. 11, 2022, Pfizer and BioNTech announced plans to extend their rolling submission to the U.S. Food…
-
Pfizer and BioNTech initiated rolling submission for EUA of COVID-19 vaccine in children 6 months through 4 years of age
On Feb. 1, 2022, Pfizer and BioNTech announced that following a request from the U.S. Food and Drug…
-
Merck and Ridgeback’s Molnupiravir, investigational antiviral COVID-19 medicine, demonstrated activity against Omicron variant
On Jan. 28, 2022, Merck and Ridgeback Biotherapeutics announced data from six preclinical studies demonstrating that molnupiravir, an…
-
Pfizer and BioNTech initiated study to evaluate Omicron-based COVID-19 vaccine in adults 18 to 55 years of age
On Jan. 25, 2022, Pfizer and BioNTech announced the initiation of a clinical study to evaluate the safety,…
